Dicer, Drosha, and Outcomes in Patients with Ovarian Cancer
- 18 December 2008
- journal article
- research article
- Published by Massachusetts Medical Society in The New England Journal of Medicine
- Vol. 359 (25), 2641-2650
- https://doi.org/10.1056/nejmoa0803785
Abstract
We studied Dicer and Drosha, components of the RNA-interference machinery, in ovarian cancer. We measured messenger RNA (mRNA) levels of Dicer and Drosha in specimens of invasive epithelial ovarian cancer from 111 patients, using a quantitative reverse-transcriptase–polymerase-chain-reaction assay, and compared the results with clinical outcomes. Validation was performed with the use of published microarray data from cohorts of patients with ovarian, breast, and lung cancer. Mutational analyses of genomic DNA from the Dicer and Drosha genes were performed in a subgroup of ovarian-cancer specimens. Dicer-dependent functional assays were performed by means of in vitro transfection with small interfering RNA (siRNA) and short hairpin RNA (shRNA). Levels of Dicer and Drosha mRNA correlated with the levels of expression of the corresponding protein and were decreased in 60% and 51% of ovarian-cancer specimens, respectively. Low Dicer expression was significantly associated with advanced tumor stage (P=0.007), and low Drosha expression with suboptimal surgical cytoreduction (P=0.02). Cancer specimens with both high Dicer expression and high Drosha expression were associated with increased median survival (>11 years, vs. 2.66 years for other subgroups; P<0.001). We found three independent predictors of reduced disease-specific survival in multivariate analyses: low Dicer expression (hazard ratio, 2.10; P=0.02), high-grade histologic features (hazard ratio, 2.46; P=0.03), and poor response to chemotherapy (hazard ratio, 3.95; P<0.001). Poor clinical outcomes among patients with low Dicer expression were validated in additional cohorts of patients. Rare missense mutations were found in the Dicer and Drosha genes, but their presence or absence did not correlate with the level of expression. Functional assays indicated that gene silencing with shRNA, but not siRNA, may be impaired in cells with low Dicer expression. Our findings indicate that levels of Dicer and Drosha mRNA in ovarian-cancer cells have associations with outcomes in patients with ovarian cancer.Keywords
This publication has 40 references indexed in Scilit:
- Medical Sequencing at the Extremes of Human Body MassAmerican Journal of Human Genetics, 2007
- Overexpression of Dicer in Precursor Lesions of Lung AdenocarcinomaCancer Research, 2007
- Genomic and transcriptional aberrations linked to breast cancer pathophysiologiesCancer Cell, 2006
- RNASEN Regulates Cell Proliferation and Affects Survival in Esophageal Cancer PatientsClinical Cancer Research, 2006
- MicroRNAs and their regulatory roles in animals and plantsJournal of Cellular Physiology, 2006
- Genetic Reclassification of Histologic Grade Delineates New Clinical Subtypes of Breast CancerCancer Research, 2006
- A role for Dicer in immune regulationThe Journal of Experimental Medicine, 2006
- MicroRNAs: A New Insight into Cancer GenomeCell Cycle, 2006
- Effects of Dicer and Argonaute down-regulation on mRNA levels in human HEK293 cellsNucleic Acids Research, 2006
- Focal Adhesion Kinase Targeting Using In vivo Short Interfering RNA Delivery in Neutral Liposomes for Ovarian Carcinoma TherapyClinical Cancer Research, 2006